Numis Securities Ltd Reiterates “Buy” Rating for Indivior PLC (INDV)
Indivior PLC (LON:INDV)‘s stock had its “buy” rating reiterated by Numis Securities Ltd in a research report issued to clients and investors on Monday, October 30th, Marketbeat reports. They presently have a GBX 500 ($6.58) price objective on the specialty pharmaceutical company’s stock. Numis Securities Ltd’s target price would indicate a potential upside of 34.30% from the company’s previous close.
A number of other analysts have also recently weighed in on the company. Citigroup Inc. reissued a “neutral” rating and issued a GBX 280 ($3.68) price objective on shares of Indivior PLC in a research report on Thursday, October 26th. Stifel Nicolaus restated a “buy” rating and issued a GBX 400 ($5.26) target price on shares of Indivior PLC in a research note on Friday, September 15th. Jefferies Group LLC reduced their target price on Indivior PLC from GBX 540 ($7.10) to GBX 358 ($4.71) and set a “buy” rating for the company in a research note on Friday, September 8th. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a GBX 470 ($6.18) target price on shares of Indivior PLC in a research note on Thursday, August 3rd. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of GBX 448.14 ($5.89).
Indivior PLC (LON:INDV) traded down GBX 9.10 ($0.12) during trading on Monday, hitting GBX 372.30 ($4.90). The stock had a trading volume of 2,705,444 shares, compared to its average volume of 2,860,000. Indivior PLC has a 52-week low of GBX 246.50 ($3.24) and a 52-week high of GBX 421.50 ($5.54).
ILLEGAL ACTIVITY NOTICE: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/30/numis-securities-ltd-reiterates-buy-rating-for-indivior-plc-indv-2.html.
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.
Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with MarketBeat.com's FREE daily email newsletter.